Augusto Afonso Guerra

List of Publications by Citations

96	1,298	18	30
papers	citations	h-index	g-index

120	1,817	2.6	4.29
ext. papers	ext. citations	avg, IF	L-index

#	Paper	IF	Citations
96	**Efficacy of Mobile Apps to Support the Care of Patients With Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.** *JMIR MHealth and UHealth*, **2017**, 5, e4	5.5	124
95	Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?. *Expert Review of Clinical Pharmacology*, **2015**, 8, 77-94	3.8	90
94	**Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets.** *Frontiers in Public Health*, **2018**, 6, 328	6	68
93	Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review. *Applied Health Economics and Health Policy*, **2014**, 12, 19-32	3.4	42
92	**Judicialization of access to medicines in Minas Gerais state, Southeastern Brazil.** *Revista De Saude Publica*, **2011**, 45, 590-8	2.4	42
91	CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety. *Journal of Comparative Effectiveness Research*, **2017**, 6, 165-180	2.1	30
90	**Epidemiological profile of patients on renal replacement therapy in Brazil, 2000-2004.** *Revista De Saude Publica*, **2010**, 44, 639-49	2.4	29
89	Quality of Life of Patients with Type 1 Diabetes Mellitus Using Insulin Analog Glargine Compared with NPH Insulin: A Systematic Review and Policy Implications. *Patient*, **2018**, 11, 377-389	3.7	27
88	**Availability of essential medicines in primary health care of the Brazilian Unified Health System.** *Revista De Saude Publica*, **2017**, 51, 10s	2.4	26
87	Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV, Dengvaxia) in Brazil; Implications for Future Pricing Considerations. *Frontiers in Pharmacology*, **2017**, 8, 41	5.6	25
86	**HEALTH TECHNOLOGY PERFORMANCE ASSESSMENT: REAL-WORLD EVIDENCE FOR PUBLIC HEALTHCARE SUSTAINABILITY.** *International Journal of Technology Assessment in Health Care*, **2017**, 33, 279-287	1.8	24
85	Quality of life of patients with Diabetes Mellitus Types 1 and 2 from a referal health centre in Minas Gerais, Brazil. *Expert Review of Clinical Pharmacology*, **2016**, 9, 739-46	3.8	23
84	**Cost-effectiveness thresholds: methods for setting and examples from around the world.** *Expert Review of Pharmacoeconomics and Outcomes Research*, **2018**, 18, 277-288	2.2	22
83	Budget impact analysis of medicines: updated systematic review and implications. *Expert Review of Pharmacoeconomics and Outcomes Research*, **2016**, 16, 257-66	2.2	22
82	**Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future.** *Frontiers in Pharmacology*, **2016**, 7, 197	5.6	22
81	National Survey on Access, Use and Promotion of Rational Use of Medicines: methods. *Revista De Saude Publica*, **2017**, 51, 4s	2.4	20
80	**Polypharmacy: a challenge for the primary health care of the Brazilian Unified Health System.** *Revista De Saude Publica*, **2017**, 51, 19s	2.4	19

79	Main characteristics of patients of primary health care services in Brazil. *Revista De Saude Publica*, **2017**, 51, 17s	2.4	17
78	Clinical Effectiveness and Safety of Analog Glargine in Type 1 Diabetes: A Systematic Review and Meta-Analysis. *Diabetes Therapy*, **2016**, 7, 241-58	3.6	16
77	Consumer willingness to pay for a hypothetical Zika vaccine in Brazil and the implications. *Expert Review of Pharmacoeconomics and Outcomes Research*, **2019**, 19, 473-482	2.2	16
76	The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil. *Pharmacoeconomics*, **2018**, 36, 161-173	4.4	16
75	Indicators related to the rational use of medicines and its associated factors. *Revista De Saude Publica*, **2017**, 51, 23s	2.4	15
74	Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil. *Applied Health Economics and Health Policy*, **2018**, 16, 697-709	3.4	15
73	Health-related quality of life of patients of Brazilian primary health care. *Revista De Saude Publica*, **2017**, 51, 22s	2.4	14
72	A construção da base de dados nacional em Terapia Renal Substitutiva (TRS) centrada no indivíduo: aplicação do método de linkage determinístico-probabilístico. *Revista Brasileira De Estudos De Populacao*, **2007**, 24,		14
71	The long-term costs for treating multiple sclerosis in a 16-year retrospective cohort study in Brazil. *PLoS ONE*, **2018**, 13, e0199446	3.7	13
70	Building the National Database of Health Centred on the Individual: Administrative and Epidemiological Record Linkage - Brazil, 2000-2015. *International Journal of Population Data Science*, **2018**, 3, 446	1.4	13
69	Pharmaceutical care in Brazil's primary health care. *Revista De Saude Publica*, **2017**, 51, 6s	2.4	12
68	Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System. *Journal of Comparative Effectiveness Research*, **2016**, 5, 539-549	2.1	12
67	Medication Persistence of Disease-Modifying Antirheumatic Drugs and Anti-Tumor Necrosis Factor Agents in a Cohort of Patients With Rheumatoid Arthritis in Brazil. *Arthritis Care and Research*, **2016**, 68, 1489-96	4.7	12
66	Integrative Review of Managed Entry Agreements: Chances and Limitations. *Pharmacoeconomics*, **2020**, 38, 1165-1185	4.4	12
65	Ten-year kidney transplant survival of cyclosporine- or tacrolimus-treated patients in Brazil. *Expert Review of Clinical Pharmacology*, **2016**, 9, 991-9	3.8	12
64	Statin use in Brazil: findings and implications. *Current Medical Research and Opinion*, **2018**, 34, 1809-1817	2.5	11
63	Stage at diagnosis and stage-specific survival of breast cancer in Latin America and the Caribbean: A systematic review and meta-analysis. *PLoS ONE*, **2019**, 14, e0224012	3.7	11
62	Perfil demográfico e epidemiológico dos usuários de medicamentos de alto custo no Sistema Único de Saúde. *Revista Brasileira De Estudos De Populacao*, **2009**, 26, 263-282		11

61	Implementation of clinical guidelines in Brazil: should academic detailing be used?. *Journal of Pharmaceutical Health Services Research*, **2016**, 7, 105-115	1	11
60	Infrastructure of pharmacies of the primary health care in the Brazilian Unified Health System: Analysis of PNAUM - Services data. *Revista De Saude Publica*, **2017**, 51, 13s	2.4	10
59	Access to medicines by patients of the primary health care in the Brazilian Unified Health System. *Revista De Saude Publica*, **2017**, 51, 20s	2.4	10
58	Pharmaceutical services in the primary health care of the Brazilian Unified Health System: advances and challenges. *Revista De Saude Publica*, **2017**, 51, 3s	2.4	10
57	Technical issues and conservation conditions of medicines in the primary health care of the Brazilian Unified Health System. *Revista De Saude Publica*, **2017**, 51, 12s	2.4	10
56	Health system modelling research: towards a whole-health-system perspective for identifying good value for money investments in health system strengthening. *BMJ Global Health*, **2019**, 4, e001311	6.6	10
55	Indicator of access to medicines in relation to the multiple dimensions of access. *Journal of Comparative Effectiveness Research*, **2019**, 8, 1027-1041	2.1	10
54	Economic and epidemiological impact of dengue illness over 16 years from a public health system perspective in Brazil to inform future health policies including the adoption of a dengue vaccine. *Expert Review of Vaccines*, **2018**, 17, 1123-1133	5.2	10
53	Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications. *Expert Review of Pharmacoeconomics and Outcomes Research*, **2017**, 17, 109-119	2.2	9
52	The clinical effectiveness of insulin glargine in patients with Type I diabetes in Brazil: findings and implications. *Journal of Comparative Effectiveness Research*, **2017**, 6, 519-527	2.1	9
51	Biological therapy in the treatment of psoriatic arthritis: economic and epidemiological considerations. *Expert Review of Clinical Immunology*, **2019**, 15, 879-887	5.1	9
50	First line of biological drugs in rheumatoid arthritis: a medication persistence analysis. *Expert Review of Clinical Pharmacology*, **2019**, 12, 363-370	3.8	9
49	Use of medicines by patients of the primary health care of the Brazilian Unified Health System. *Revista De Saude Publica*, **2017**, 51, 18s	2.4	9
48	Medicine dispensing service in primary health care of SUS. *Revista De Saude Publica*, **2017**, 51, 11s	2.4	9
47	Conceptions on pharmaceutical services in Brazilian primary health care. *Revista De Saude Publica*, **2017**, 51, 5s	2.4	9
46	Workforce in the pharmaceutical services of the primary health care of SUS, Brazil. *Revista De Saude Publica*, **2017**, 51, 16s	2.4	9
45	Real-world evaluation of the impact of statin intensity on adherence and persistence to therapy: A Scottish population-based study. *British Journal of Clinical Pharmacology*, **2020**, 86, 2349-2361	3.8	8
44	Patient satisfaction with pharmaceutical services in Brazilian primary health care. *Revista De Saude Publica*, **2017**, 51, 21s	2.4	8

43	Management of pharmaceutical services in the Brazilian primary health care. *Revista De Saude Publica*, **2017**, 51, 15s	2.4	8
42	Effectiveness and safety of insulin glargine detemir analysis in patients with type 1 diabetes: systematic review and meta-analysis. *Therapeutic Advances in Endocrinology and Metabolism*, **2018**, 9, 241-254	4.5	8
41	Who should pay for the continuity of post-trial health care treatments?. *International Journal for Equity in Health*, **2019**, 18, 26	4.6	7
40	Rituximabe para o tratamento da artrite reumatoide: Revisão sistemática. *Revista Brasileira De Reumatologia*, **2014**, 54, 220-230		7
39	Cyclosporine versus tacrolimus in immunosuppressive maintenance regimens in renal transplants in Brazil: survival analysis from 2000 to 2004. *Annals of Pharmacotherapy*, **2010**, 44, 192-201	2.9	7
38	Comparative persistence of anti-tumor necrosis factor therapy in ankylosing spondylitis patients: a multicenter international study. *Current Medical Research and Opinion*, **2020**, 36, 677-686	2.5	7
37	Acceptability and willingness to pay for a hypothetical vaccine against SARS CoV-2 by the Brazilian consumer: a cross-sectional study and the implications. *Expert Review of Pharmacoeconomics and Outcomes Research*, **2021**, 1-11	2.2	7
36	Access to medicines: relations with the institutionalization of pharmaceutical services. *Revista De Saude Publica*, **2017**, 51, 8s	2.4	6
35	Effectiveness of Maintenance Immunosuppression Therapies in a Matched-Pair Analysis Cohort of 16 Years of Renal Transplant in the Brazilian National Health System. *International Journal of Environmental Research and Public Health*, **2020**, 17,	4.6	5
34	Financing of Pharmaceutical Services in the municipal management of the Brazilian Unified Health System. *Revista De Saude Publica*, **2017**, 51, 14s	2.4	5
33	Characterization of the institutionalization of pharmaceutical services in Brazilian primary health care. *Revista De Saude Publica*, **2017**, 51, 7s	2.4	5
32	Pharmaceutical services in primary health care: interfederative agreement in the development of pharmaceutical policies in the Brazilian Unified Health System (SUS). *Revista De Saude Publica*, **2017**, 51, 2s	2.4	5
31	Cyclosporine versus tacrolimus: cost-effectiveness analysis for renal transplantation in Brazil. *Revista De Saude Publica*, **2015**, 49, 13	2.4	5
30	Pesquisa e produção científica em economia da saúde no Brasil. *Revista De Administracao Publica*, **2007**, 41, 211-235	0.4	5
29	Confidentiality agreements: a challenge in market regulation. *International Journal for Equity in Health*, **2019**, 18, 11	4.6	4
28	Characterization of the selection of medicines for the Brazilian primary health care. *Revista De Saude Publica*, **2017**, 51, 9s	2.4	4
27	Cost Analysis of Cancer in Brazil: A Population-Based Study of Patients Treated by Public Health System From 2001-2015. *Value in Health Regional Issues*, **2020**, 23, 137-147	1.6	4
26	Anlise da Produ de Avalia de Tecnologias Em Sade do Centro Colaborador do Sistema ico de Sade (Sus), Brasil - Uma Parceria Entre o Governo E A Academia. *Value in Health*, **2015**, 18, A848	3.3	2

25	AuthorsSreply to Dr. Malerbi: "Insulin glargine in a Brazilian state: should the government disinvest?". *Applied Health Economics and Health Policy*, **2014**, 12, 561-3	3.4	2
24	A demographic and clinical panorama of a sixteen-year cohort of soft tissue sarcoma patients in Brazil. *Scientific Reports*, **2021**, 11, 22501	4.9	2
23	Avalia normativa do processo de prescri e dispensa de imunossupressores para pacientes transplantados renais no estado de Minas Gerais, Brasil, 2008. *Epidemiologia E Servicos De Saude: Revista Do Sistema Unico De Saude Do Brasil*, **2013**, 22, 651-660	1.2	2
22	A cross-sectional study of the quality of life of patients living with type 1 diabetes treated with insulin glargine and neutral protamine Hagedorn insulin and the implications. *Journal of Pharmaceutical Health Services Research*, **2021**, 12, 332-342	1	2
21	Academic detailing program for rheumatoid arthritis: a contribution to Brazilian public health system sustainability. *Journal of Pharmaceutical Health Services Research*, **2020**, 11, 249-254	1	1
20	Funding and Service Organization to Achieve Universal Health Coverage for Medicines: An Economic Evaluation of the Best Investment and Service Organization for the Brazilian Scenario. *Frontiers in Pharmacology*, **2020**, 11, 370	5.6	1
19	Rituximab for rheumatoid arthrits treatment: a systematic review. *Revista Brasileira De Reumatologia*, **2014**, 54, 220-230		1
18	Real-world effectiveness of olanzapine and risperidone in the treatment of schizophrenia in Brazil over a 16-year follow-up period; findings and implications. *Expert Review of Clinical Pharmacology*, **2021**, 14, 269-279	3.8	1
17	Influence of pharmaceutical services organization on the availability of essential medicines in a public health system. *Journal of Comparative Effectiveness Research*, **2021**, 10, 519-532	2.1	1
16	Budget impact analysis of medicines: estimated values versus real-world evidence and the implications. *Expert Review of Pharmacoeconomics and Outcomes Research*, **2021**, 1-11	2.2	1
15	Prostate Cancer Survival and Mortality according to a 13-year retrospective cohort study in Brazil: Competing-Risk Analysis. *Revista Brasileira De Epidemiologia*, **2021**, 24, e210006	1.3	1
14	Strategies to improve the availability of medicines in primary health care in Brazil: findings and implications. *Journal of Comparative Effectiveness Research*, **2021**, 10, 243-253	2.1	1
13	The Price of Substitute Technologies. *Value in Health Regional Issues*, **2019**, 20, 154-158	1.6	0
12	Use of medicines by adults in primary care: Survey on health services in Minas Gerais, Brazil. *Revista Brasileira De Epidemiologia*, **2020**, 23, e200025	1.3	0
11	Sixteen-Year Cohort of Liver Transplantation in the National Health System in Brazil: Analysis of Immunosuppression Maintenance Therapies. *Frontiers in Pharmacology*, **2020**, 11, 572043	5.6	0
10	Social and economic factors associated with antidepressant use: Results of a national survey in primary care. *Journal of Affective Disorders Reports*, **2022**, 8, 100307	1.4	0
9	Effectiveness of first-line treatment for relapsing-remitting multiple sclerosis in Brazil: A 16-year non-concurrent cohort study. *PLoS ONE*, **2020**, 15, e0238476	3.7	0
8	Sixteen Years of Heart Transplant in an Open Cohort in Brazil: Analysis of Graft Survival of Patients using Immunosuppressants. *Arquivos Brasileiros De Cardiologia*, **2021**, 116, 744-753	1.2	0

7	Access to medicines in the Brazilian Unified Health System's primary health care: assessment of a public policy. *Journal of Comparative Effectiveness Research*, **2021**, 10, 869-879	2.1	0
6	Cost-minimization analysis of teledermatology versus conventional care in the Brazilian National Health System. *Journal of Comparative Effectiveness Research*, **2021**, 10, 1159-1168	2.1	0
5	Survival Analysis of COPD Patients in a 13-Year Nationwide Cohort Study of the Brazilian National Health System.. *Frontiers in Big Data*, **2021**, 4, 788268	2.8	
4	Perfil e gastos dos pacientes dislipidêmicos usuários do componente especializado da assistência farmacêutica do Sistema Único de Saúde. *Physis*, **2013**, 23, 1215-1227	0.8	
3	Polypharmacy among adult and older adult users of primary care services delivered through the Unified Health System in Minas Gerais, Brazil. *Expert Review of Clinical Pharmacology*, **2020**, 13, 1401-1409	3.8	
2	Comorbidities and in-hospital death of viral pneumonia adults admitted to SUS (2002-2015). *Revista De Saude Publica*, **2021**, 55, 43	2.4	
1	Conventional Synthetic Disease-Modifying Anti-rheumatic Drugs for Psoriatic Arthritis: Findings and Implications From a Patient Centered Longitudinal Study in Brazil.. *Frontiers in Pharmacology*, **2022**, 13, 878972	5.6	